This site is intended for Healthcare Professionals only

Congratulations on completing this module  (0% complete)

quiz close icon

module menu icon Recognising differentiating symptoms

Recognising differentiating symptoms

Other conditions may present with symptoms similar to hay fever.2 These conditions do not warrant use of Dymista® Control and alternative therapies or referral to a doctor should be considered. Therefore, it is important to carefully assess symptoms to ensure appropriate treatment.

Click through the carousel below for information that may help to assess your customer’s symptoms. Full information on differential diagnoses can be found in the Pharmacy Essential Guide.

TIMING OF SYMPTOMS

When do symptoms occur? What could it be?

Around the same time each year, in response to grass, tree and/or weed pollen2

Hay fever (seasonal AR)

All year round, in response to house mites, mould or animal dander2

Perennial AR

All year round, due to exposure to allergens in the work environment2

Occupational AR

Symptoms coincide with pregnancy, starting the oral contraceptive pill, hormone replacement therapy (HRT) or hypothyroidism2

Hormonal rhinitis

Symptoms typically follow known exposure to a physical cause or chemical irritant2

Autonomic or irritant rhinitis

ONSET OF SYMPTOMS

How quickly do symptoms appear? What could it be?

Within minutes after exposure to pollen12

Hay fever (seasonal AR)

Gradually over 2-3 days13

Common cold or infective rhinitis

DURATION OF SYMPTOMS

How long do symptoms last? What could it be?

Weeks or even months14

Hay fever (seasonal AR)

1-2 weeks14

Common cold or infective rhinitis

PRESENCE OF FEVER

Despite its name, hay fever is not generally associated with a raised body temperature.

If a fever is present alongside symptoms similar to hay fever, consider whether your customer has a common cold or infective rhinitis, sinusitis, a chest infection, tuberculosis or granulomatosis with polyangiitis (GPA).10

BILATERAL SYMPTOMS

Symptoms of hay fever are usually bilateral; affecting both sides of the nose and/or both eyes.2

If your customer has unilateral symptoms, this is more likely to indicate nasal structural abnormalities or a blockage, such as polyps or the presence of a foreign body.2

NASAL DISCHARGE AND/OR NOSEBLEEDS

Rhinorrhoea, a classic symptom of hay fever, is a runny nose with clear, thin mucus.2

Differentiating symptoms Could it be... ?

Discoloured nasal discharge2,13

Common cold or infective rhinitis

Green or yellow mucus from the nose

Sinusitis15

Recurrent bloody discharge or nosebleeds

Nasal structural abnormalities2

ASSOCIATED COUGH

Hay fever can be associated with a cough due to a post-nasal drip irritating the throat.16

If you or your customer are concerned about their cough, e.g. due to its duration, persistence, the presence of blood, or because they are really unwell, you should refer them to their GP for further investigation.17

ASSOCIATED BREATHING DIFFICULTIES

Hay fever may be associated with possible mouth breathing due to nasal congestion, but no breathing difficulties or shortness of breath.2

If your customer has shortness of breath, is wheezing, has other breathing difficulties or chest/arm/jaw pain you should consider an alternative diagnosis, such as asthma, a chest infection or a cardiovascular condition.10

MEDICATION AND RECREATIONAL DRUGS

Hay fever is caused by an allergic reaction due to exposure to pollen.2

Rhinitis may be caused by medication such as alpha-blockers, ACE inhibitors, beta-blockers, chlorpromazine, aspirin, NSAIDs and phosphodiesterase inhibitors. It may also occur as a result of recreational drug use, e.g. cocaine.10

Rebound symptoms and a paradoxical increase in nasal congestion may occur when stopping prolonged treatment with intranasal decongestants due to rebound vasodilatation.2

When a diagnosis of hay fever cannot be determined using this guidance together with information available in the Pharmacy Essential Guide, the customer must be referred to a doctor.


Summary

If a customer 18 years or older is suffering from moderate to severe hay fever and monotherapy with either an intranasal antihistamine or intranasal corticosteroid is not considered sufficient, and they have no contraindications and are not taking medication that may interact, Dymista® Control nasal spray may be supplied with appropriate advice.

Click on each heading below to see example questions that can help you ascertain Dymista® Control’s suitability for adult customers (18 years or over):

Determine your customer's diagnosis

“WHAT ARE YOUR MAIN SYMPTOMS?”

This will indicate whether they are likely to suffer from hay fever (e.g. runny nose, sneezing, itchy nose, nasal congestion, itchy, red, watery eyes; check for bilateral symptoms)

“WHEN DID YOUR SYMPTOMS START?”

This will help to determine whether symptoms coincide with pollen season and also provide information on duration


Classify the impact of their symptoms

“DO YOUR SYMPTOMS IMPACT YOUR LIFE?”

This will help to determine whether they are suffering from moderate to severe symptoms, i.e. symptoms are troublesome, they cause disturbed sleep, problems at work and/or studies and impairment of daily activities, sport or leisure


Evaluate their current treatment

“WHAT TREATMENT(S) HAVE YOU TRIED ALREADY?”

This will help to determine whether monotherapy with either intranasal antihistamine or intranasal corticosteroid has been tried without providing sufficient symptom relief


Consider their associated health conditions

“DO YOU HAVE ANY OTHER MEDICAL CONDITIONS OR ARE YOU TAKING ANY OTHER MEDICATION?”

This will help to determine whether Dymista® Control nasal spray may be an appropriate option or whether the customer should be referred to a doctor

References

1. Dymista® Control 137 microgram, 50 microgram nasal spray. SmPC. 2025. Available at: https://www.medicines.org.uk/emc/product/100435/smpc

2. NICE. CKS. Allergic rhinitis. 2024. Available at: https://cks.nice.org.uk/topics/allergic-rhinitis/

3. NHS. Steroid nasal sprays. 2023. Available at: https://www.nhs.uk/conditions/steroid-nasal-sprays/

4. BNF. Antihistamines. 2025.
Available at: https://bnf.nice.org.uk/treatment-summaries/antihistamines-allergen-immunotherapy-and-allergic-emergencies/#antihistamines

5. Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007).
Clin Exp Allergy. 2017; 47:856–889. DOI: 10.1111/cea.12953

6. Benadryl Allergy Relief (P). SmPC. 2020. Available at: https://www.medicines.org.uk/emc/product/3388/smpc/print

7. Zirtek Allergy 10 mg film-coated Tablets. SmPC. 2023. Available at: https://www.medicines.org.uk/emc/product/6751/smpc/print

8. Allevia 120mg tablets. SmPC. 2023. Available at: https://www.medicines.org.uk/emc/product/13208/smpc/print

9. Clarityn Allergy 10mg Tablets (P). SmPC. 2023. Available at: https://www.medicines.org.uk/emc/product/3505/smpc/print

10. Dymista® Control 137 microgram, 50 microgram nasal spray. Pharmacy Essential Guide. 2025.
Available at: https://www.medicines.org.uk/emc/product/100435/rmms

11. Dymista® Control 137 microgram, 50 microgram nasal spray. PIL. 2024. Available at: https://www.medicines.org.uk/emc/files/pil.100435.pdf

12. NHS. Allergic rhinitis. 2022. Available at: https://www.nhs.uk/conditions/allergic-rhinitis/

13. NHS. Common cold. 2024. Available at: https://www.nhs.uk/conditions/common-cold/

14. NHS. Hay fever. 2024. Available at: https://www.nhs.uk/conditions/hay-fever/

15. NHS. Sinusitis. 2024. Available at: https://www.nhs.uk/conditions/sinusitis-sinus-infection/

16. McKechnie D. Hay fever. 2023. Available at: https://patient.info/allergies-blood-immune/hay-fever-leaflet#hay-fever-symptoms

17. NHS. Cough. 2023. Available at: https://www.nhs.uk/conditions/cough/

Online sources last accessed March 2025.

Product information

Please refer to the Summary of product characteristics (SmPC) for full information before recommending this product.

Dymista® Control 137 micrograms / 50 micrograms per Actuation Nasal Spray. Contains azelastine hydrochloride and fluticasone propionate.
Indication: Relief of symptoms of moderate to severe seasonal allergic rhinitis in adults if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient. Dosage and method of use: 18 years of age or over: The recommended dose is one actuation in each nostril twice daily (morning and evening). The maximum daily dose should not exceed 2 sprays in each nostril per day. Dymista® Control Nasal Spray should not be used in children and adolescents under 18 years of age. Dymista® Control Nasal Spray is for nasal use only.
Contra-indications: Hypersensitivity to the active substance or to any of the excipients. Warnings and Precautions: Treatment should be stopped, or the advice of a doctor sought if an improvement is not seen within 7 days. The advice of a doctor or pharmacist should also be sought if symptoms have improved but are not adequately controlled within 7 days. This medicine should not be used for more than 3 months continuously without consulting a doctor.
Medical advice should be sought before using this medicine in the case of:

  • concomitant use of other corticosteroid products, such as tablets, creams, ointments, asthma medications, similar nasal sprays, or eye/nose drops.

  • fever or an infection in the nasal passages or sinuses.

  • recent injury or surgery to the nose, or problems with ulceration in the nose.

Clinically significant drug interactions in patients receiving fluticasone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression. Therefore, concomitant use of fluticasone propionate and ritonavir should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side-effects.
Systemic effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations. Potential systemic effects may include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression, or aggression. Dymista® Control Nasal Spray undergoes extensive first-pass metabolism, therefore the systemic exposure of intranasal fluticasone propionate in patients with severe liver disease is likely to be increased. This may result in a higher frequency of systemic adverse events. Caution is advised in these patients. Treatment with higher than recommended doses of nasal corticosteroids may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used, then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. In general, the dose of intranasal fluticasone formulations should be reduced to the lowest dose at which effective control of the symptoms of rhinitis is maintained. Higher doses than the recommended one have not been tested for Dymista® Control. As with all intranasal corticosteroids, the total systemic burden of corticosteroids should be considered whenever other forms of corticosteroid treatment are prescribed concurrently. Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids. Close monitoring is warranted in patients with a change in vision or with a history of increased ocular pressure, glaucoma and/or cataracts. If there is any reason to believe that adrenal function is impaired, care must be taken when transferring patients from systemic steroid treatment to Dymista® Control Nasal Spray. In patients who have tuberculosis, any type of untreated infection, or have had a recent surgical operation or injury to the nose or mouth, the possible benefits of the treatment with Dymista® Control Nasal Spray should be weighed against possible risk. Infections of the nasal airways should be treated with antibacterial or antimycotical therapy, but do not constitute a specific contraindication to treatment with Dymista® Control Nasal Spray. Dymista® Control Nasal Spray contains benzalkonium chloride. Long term use may cause oedema of the nasal mucosa. Side-effects: Very Common (≥1/10): Epistaxis. Common (≥1/100 and <1/10): Headache, dysgeusia (unpleasant taste), unpleasant smell. Uncommon (≥1/1,000 and <1/100): Nasal discomfort (including nasal irritation, stinging, itching), sneezing, nasal dryness, cough, dry throat, throat irritation. Rare (≥1/10,000 and <1/1000): Dry mouth. Very rare (<1/10,000): Hypersensitivity including anaphylactic reactions, angioedema (oedema of the face or tongue and skin rash), bronchospasm, dizziness, somnolence, glaucoma, increased intraocular pressure, cataract, nasal septal perforation, mucosal erosion, nausea, rash, pruritus, urticaria, fatigue, weakness. Side effects where the frequency cannot be estimated from available data: blurred vision, nasal ulcers. Systemic effects of some nasal corticosteroids may occur, particularly when administered at high doses for prolonged periods. In rare cases osteoporosis was observed if nasal glucocorticoids were administered long-term. Product licence number: PL 46302/0094 Name and address of the product licence holder: Mylan Products Ltd, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom. Supply classification: P. Cost: £13.72 (Trade price) Document number: UK-DTC-2024-00044. Date last revised: December 2024

Change privacy settings